I congratulate Drs. Bichuetti and Oliveira for the report of their experience with IVIG as a maintenance therapy for NMO, which appeared after submission of this article for publication. I look forward to publication of their full data and agree that there are several potential methods by which IVIG could be employed as chronic immunotherapy, including as a single agent, as part of a combination strategy, or as an "induction therapy" or bridge to other agents. As they point out, there are regions where certain immunotherapies or plasma exchange are impractical and IVIG deserves further exploration as a treatment option in carefully designed prospective studies.
